Arch Biopartners Inc.

Arch Biopartners Inc. is a therapeutic biotechnology company based in Toronto, Canada, focused on developing novel drugs for acute and chronic kidney diseases, as well as organ damage caused by inflammation and toxins. The company's mission is to address significant unmet medical needs in global kidney care by targeting specific biological drivers of injury.

The company's pipeline centers on the dipeptidase-1 (DPEP1) pathway and includes several drug candidates. Its lead drug candidate, LSALT peptide, is in Phase II clinical trials for cardiac surgery-associated acute kidney injury (CS-AKI). Arch Biopartners is also developing Cilastatin, a repurposed DPEP1 inhibitor, as a treatment for drug toxin-related acute kidney injury, also in Phase II. Additionally, the company is advancing a pre-clinical platform targeting IL-32 for chronic kidney disease, particularly diabetic kidney disease.

Arch Biopartners is a publicly traded company with its shares listed on the TSX Venture Exchange under the symbol ARCH and on the OTCQB market under the symbol ACHFF. Key leadership includes CEO Richard Muruve, CSO Daniel Muruve, and CFO Andrew Bishop. Recent activities include closing non-brokered private placements in March and April 2026, and ongoing patient recruitment and dosing in its Phase II clinical trials for LSALT peptide.

Latest updates

Arch Biopartners Expands Canadian Trial Sites for AKI Drug

Event summary

  • Arch Biopartners’ Phase II trial for LSALT peptide, targeting CS-AKI (cardiac surgery-associated acute kidney injury), has added Royal Columbian Hospital as the ninth global site and fourth Canadian site.
  • Patient recruitment is already underway at three other major Canadian sites: Toronto General Hospital, St. Michael’s Hospital, and the University of Calgary.
  • The trial aims to enroll 240 patients and evaluate the effectiveness of LSALT peptide in reducing AKI rates following on-pump cardiac surgery.
  • Arch is actively pursuing additional sites in Canada and the United States, with discussions ongoing for three US sites and one Ontario site.

The big picture

The expansion of the CS-AKI trial underscores the ongoing need for effective treatments for acute kidney injury, a complication affecting a significant portion of patients undergoing cardiac surgery. Arch’s focus on targeted peptide therapies represents a shift towards more precise interventions in kidney care, but the success of the trial remains contingent on demonstrating efficacy and navigating the complexities of clinical development and regulatory approval.

What we're watching

Enrollment Pace
The speed of patient enrollment across the expanded sites will be critical to the trial’s timeline and ultimate success, potentially impacting Arch’s financial projections.
Regulatory Risk
The ongoing discussions with US sites highlight potential regulatory hurdles and delays that could impact the trial’s scope and timeline.
Competitive Landscape
The trial’s results will be weighed against emerging therapies for AKI, and Arch’s ability to demonstrate a clear advantage will be crucial for commercial viability.
CID: 1281